ES3023754T3 - Terlipressin composition for use in treating ascites - Google Patents
Terlipressin composition for use in treating ascites Download PDFInfo
- Publication number
- ES3023754T3 ES3023754T3 ES17862085T ES17862085T ES3023754T3 ES 3023754 T3 ES3023754 T3 ES 3023754T3 ES 17862085 T ES17862085 T ES 17862085T ES 17862085 T ES17862085 T ES 17862085T ES 3023754 T3 ES3023754 T3 ES 3023754T3
- Authority
- ES
- Spain
- Prior art keywords
- terlipressin
- composition
- subject
- administered
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410971P | 2016-10-21 | 2016-10-21 | |
| US201762472291P | 2017-03-16 | 2017-03-16 | |
| PCT/US2017/057601 WO2018075897A1 (en) | 2016-10-21 | 2017-10-20 | Terlipressin compositions and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3023754T3 true ES3023754T3 (en) | 2025-06-03 |
Family
ID=62019439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17862085T Active ES3023754T3 (en) | 2016-10-21 | 2017-10-20 | Terlipressin composition for use in treating ascites |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10993984B2 (enExample) |
| EP (2) | EP3528828B1 (enExample) |
| JP (3) | JP2020500164A (enExample) |
| AU (2) | AU2017345720B2 (enExample) |
| CA (1) | CA3037581A1 (enExample) |
| ES (1) | ES3023754T3 (enExample) |
| IL (2) | IL313083A (enExample) |
| MA (1) | MA46586A (enExample) |
| WO (1) | WO2018075897A1 (enExample) |
| ZA (1) | ZA201901912B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2629131T3 (es) | 2008-09-17 | 2017-08-07 | Chiasma Inc. | Composiciones farmacéuticas y métodos de suministro relacionados. |
| RS66942B1 (sr) | 2015-02-03 | 2025-07-31 | Amryt Endo Inc | Lečenje akromegalije oralnim oktreotidom |
| CN109223720B (zh) * | 2018-09-12 | 2020-11-27 | 南京康舟医药科技有限公司 | 注射用醋酸特利加压素冻干粉针剂的制备方法 |
| WO2021127234A2 (en) * | 2019-12-20 | 2021-06-24 | Northwestern University | Terlipressin-octadecanedioic acid conjugate for vasoconstrictive therapy |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN114306250B (zh) * | 2021-11-26 | 2023-07-14 | 苏州天马医药集团天吉生物制药有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH455823A (de) | 1964-08-01 | 1968-05-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von Peptiden |
| EP1188443A1 (en) * | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
| RU2415149C2 (ru) | 2006-02-10 | 2011-03-27 | Ферринг Б.В. | Пептидные соединения |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| ES2629131T3 (es) * | 2008-09-17 | 2017-08-07 | Chiasma Inc. | Composiciones farmacéuticas y métodos de suministro relacionados. |
| US20110311621A1 (en) * | 2010-03-16 | 2011-12-22 | Paul Salama | Pharmaceutical compositions and methods of delvery |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| JO3371B1 (ar) | 2013-07-26 | 2019-03-13 | Ferring Bv | ناهضات مستقبل فاسوبريسين 2 |
| ES2987577T3 (es) * | 2014-10-24 | 2024-11-15 | Mallinckrodt Pharmaceuticals Ireland Ltd | Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1 |
| EP3247376B1 (en) | 2015-03-30 | 2021-07-14 | Sunnybrook Research Institute | Treating prostate cancer |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2017
- 2017-10-20 ES ES17862085T patent/ES3023754T3/es active Active
- 2017-10-20 WO PCT/US2017/057601 patent/WO2018075897A1/en not_active Ceased
- 2017-10-20 CA CA3037581A patent/CA3037581A1/en active Pending
- 2017-10-20 MA MA046586A patent/MA46586A/fr unknown
- 2017-10-20 AU AU2017345720A patent/AU2017345720B2/en active Active
- 2017-10-20 IL IL313083A patent/IL313083A/en unknown
- 2017-10-20 JP JP2019521093A patent/JP2020500164A/ja not_active Withdrawn
- 2017-10-20 EP EP17862085.2A patent/EP3528828B1/en active Active
- 2017-10-20 US US16/343,232 patent/US10993984B2/en active Active
- 2017-10-20 EP EP25152377.5A patent/EP4516803A3/en active Pending
- 2017-10-20 IL IL265761A patent/IL265761B2/en unknown
-
2019
- 2019-03-27 ZA ZA2019/01912A patent/ZA201901912B/en unknown
-
2021
- 2021-11-11 US US17/524,022 patent/US20220313773A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108121A patent/JP2023120445A/ja not_active Withdrawn
- 2023-10-27 AU AU2023255036A patent/AU2023255036A1/en active Pending
-
2024
- 2024-01-31 US US18/429,227 patent/US20250000933A1/en active Pending
- 2024-11-06 JP JP2024194379A patent/JP2025020319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023255036A1 (en) | 2023-11-16 |
| JP2020500164A (ja) | 2020-01-09 |
| US10993984B2 (en) | 2021-05-04 |
| US20250000933A1 (en) | 2025-01-02 |
| IL265761B1 (en) | 2024-07-01 |
| IL265761A (en) | 2019-06-30 |
| AU2017345720A1 (en) | 2019-04-11 |
| CA3037581A1 (en) | 2018-04-26 |
| MA46586A (fr) | 2019-08-28 |
| EP3528828A1 (en) | 2019-08-28 |
| WO2018075897A1 (en) | 2018-04-26 |
| IL313083A (en) | 2024-07-01 |
| EP4516803A2 (en) | 2025-03-05 |
| JP2023120445A (ja) | 2023-08-29 |
| US20220313773A1 (en) | 2022-10-06 |
| EP3528828B1 (en) | 2025-01-29 |
| AU2017345720B2 (en) | 2023-07-27 |
| NZ751717A (en) | 2025-05-02 |
| ZA201901912B (en) | 2023-10-25 |
| JP2025020319A (ja) | 2025-02-12 |
| US20190240284A1 (en) | 2019-08-08 |
| EP4516803A3 (en) | 2025-06-25 |
| IL265761B2 (en) | 2024-11-01 |
| EP3528828A4 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3023754T3 (en) | Terlipressin composition for use in treating ascites | |
| ES2762250T5 (es) | Tratamiento combinado del cáncer | |
| ES2227301T3 (es) | Composicion farmaceutica inyectable para la administracion sistematica de principios farmacologicamente activos que contienen trigliceridos de cadena media. | |
| JP5973909B2 (ja) | 前立腺癌を治療するための組成物 | |
| ES2271772T3 (es) | Metodos y composiciones farmaceuticas para consecucion fiable de niveles aceptables de testosterona en suero. | |
| EP2635269B1 (en) | A combination composition | |
| ES2896971T3 (es) | Formas de administración de hormona del crecimiento de acción prolongada | |
| ES2865278T3 (es) | Amantadina para mejorar la marcha en esclerosis múltiple | |
| KR20210118883A (ko) | 레시니페라톡신을 투여하여 골관절염 통증을 치료하는 방법 | |
| ES2604254T3 (es) | Combinaciones de flurbiprofeno de liberación controlada y relajante muscular | |
| CN110709061A (zh) | 抗沉淀的小分子药物制剂 | |
| ES2973119T3 (es) | Combinación de ibudilast e interferón-beta y métodos de uso | |
| ES2761311T3 (es) | Tratamiento terapéutico | |
| HK40120596A (en) | Terlipressin compositions and their methods of use | |
| KR20200018438A (ko) | 향상된 용해도의 약물-함유 제형 | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| JP4880845B2 (ja) | Ｇｒｆ含有凍結乾燥薬剤組成物 | |
| KR20100013515A (ko) | 온단세트론의 직장내 투여를 위한 온도 감응성 액상좌제조성물 | |
| Mistry et al. | Time and site specific gastro-retentive floating pulsatile drug delivery system: a review | |
| JP2019517490A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
| KR20170099911A (ko) | 파라세타몰 주사 제제 | |
| WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
| JP2022552336A (ja) | 造血器悪性腫瘍を治療するための併用療法 | |
| KR20060123329A (ko) | 월경 곤란증의 예방 및/또는 치료제 |